- Home
- CLDI vs VIVS Comparison
CLDI vs VIVS Comparison
Compare CLDI & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLDI
- VIVS
- Stock Information
- Founded
- CLDI 2014
- VIVS 2007
- Country
- CLDI United States
- VIVS United States
- Employees
- CLDI N/A
- VIVS N/A
- Industry
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- VIVS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CLDI Health Care
- VIVS Health Care
- Exchange
- CLDI Nasdaq
- VIVS Nasdaq
- Market Cap
- CLDI 8.7M
- VIVS 8.1M
- IPO Year
- CLDI N/A
- VIVS N/A
- Fundamental
- Price
- CLDI $1.49
- VIVS $2.21
- Analyst Decision
- CLDI
- VIVS
- Analyst Count
- CLDI 0
- VIVS 0
- Target Price
- CLDI N/A
- VIVS N/A
- AVG Volume (30 Days)
- CLDI 231.9K
- VIVS 1.4M
- Earning Date
- CLDI 11-07-2025
- VIVS 11-06-2025
- Dividend Yield
- CLDI N/A
- VIVS N/A
- EPS Growth
- CLDI N/A
- VIVS N/A
- EPS
- CLDI N/A
- VIVS N/A
- Revenue
- CLDI N/A
- VIVS $140,000.00
- Revenue This Year
- CLDI N/A
- VIVS $42.38
- Revenue Next Year
- CLDI N/A
- VIVS $15.42
- P/E Ratio
- CLDI N/A
- VIVS N/A
- Revenue Growth
- CLDI N/A
- VIVS 35.92
- 52 Week Low
- CLDI $1.10
- VIVS $1.41
- 52 Week High
- CLDI $46.68
- VIVS $21.96
- Technical
- Relative Strength Index (RSI)
- CLDI 47.51
- VIVS 43.71
- Support Level
- CLDI $1.10
- VIVS $2.09
- Resistance Level
- CLDI $1.56
- VIVS $2.46
- Average True Range (ATR)
- CLDI 0.14
- VIVS 0.27
- MACD
- CLDI 0.01
- VIVS -0.00
- Stochastic Oscillator
- CLDI 69.49
- VIVS 18.26
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.
About VIVS VivoSim Labs Inc. Common Stock
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.